| dc.contributor.author | Pawan Kumar Sah | |
| dc.date.accessioned | 2022-08-02T05:01:36Z | |
| dc.date.available | 2022-08-02T05:01:36Z | |
| dc.date.issued | 2022-05 | |
| dc.identifier.uri | http://10.10.11.6/handle/1/9992 | |
| dc.language.iso | en | en_US |
| dc.publisher | GALGOTIAS UNIVERSITY | en_US |
| dc.subject | Cancer, anticancer agents, benzimidazole, broadness of cancer, advancement, resistance, target-based derivatives, synthesis, application, ADRs | en_US |
| dc.subject | The incidence of cancer is increasing worldwide, affecting a vast majority of the human population, therefore, new different anticancer agents are being developed now and their safety still needs to be evaluated. Among them, benignidazole based drugs are contributing a lot, as they are one of the imperative pharmacophores occurring synthetically as well as naturally in heterocyclic compounds, having a wide-range of therapeutic applications in the area of drug discovery that offers many chances for further improvement in antitumor agents via acting onto numerous receptors of extreme prominence. | en_US |
| dc.title | RECENT ADVANCEMENT OF BENZIMIDAZOLE IN TREATMENT OF CANCER | en_US |
| dc.type | Other | en_US |
